Reduction of IOP in adult patients w/ open angle glaucoma or ocular HTN who are insufficiently responsive to topical monotherapy w/ β-blockers or prostaglandin analogues & require a combination therapy.
Hypersensitivity. Patients w/ or history of bronchial asthma, severe chronic COPD; poor-controlled cardiac failure, sinus bradycardia, 2nd- or 3rd-degree AV block, cardiogenic shock. Combination w/ omidenepag isopropyl.
Patients w/ right ventricular failure caused by pulmonary HTN, CHF, diabetic ketoacidosis or metabolic acidosis, poor-controlled diabetes, aphakia or pseudophakia, intraocular inflammation (iritis, uveitis). This may be absorbed systemically & cause adverse drug reactions similar to those caused by systemic administration of a β-blocker. Pigmentation in iris & eyelid or hypertrichosis around the eyes may occur. Corneal epithelium disorder (superficial punctate keratitis, filamentary keratitis or corneal erosion) may occur during treatment. Closed angle glaucoma. Concomitant use w/ β-blockers. Switch from a miotic may require refraction adjustment. Instill w/in 5 min interval if other ophth drug is used. Remove contact lenses prior to administration & re-insert after at least 15 min. Pregnancy & lactation, parturient women. Elderly. Childn, infants (low birth wt) & neonates.
Sign Out
